New Zealand initiates isledovanija aimed at clarifying the possibility of using cannabis as a therapeutic agent
The government has established a working group tasked with comprehensive study of the positive and negative sides of the legalization of the use of psychoactive cannabis in the medical field.
The group in addition to representatives of relevant government agencies including leading scientists dealing with this issue, and doctors practicing medicine cannabinoid use in their countries. In addition to experts from Australia and Oceania, several well-known representatives of the market of medical cannabis from the United States and Europe in the group include representatives of public organizations of New Zealand. "The public concerned" to participate in all meetings on the subject and conducted within the framework of research activities in an advisory capacity, which will be obliged to heed the representatives of the Department of Health of the country.
The study is divided into several phases, the first of which is to conduct a clinical trial designed to study the possibility of using cannabis as a therapeutic agent in New Zealand.